Chemo-Immunotherapy Regimes for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis

Introduction: In 2021, two phase III clinical trials confirmed that toripalimab or camrelizumab combined with gemcitabine and cisplatin (TGP or CGP) provide more benefits in the first-line treatment of R/M NPC than GP. Fortunately, TGP and CGP were recently approved as first-line treatments for case...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Youwen, Liu, Kun, Ding, Dong, Wang, Kailing, Liu, Xiaoting, Tan, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163401/
https://www.ncbi.nlm.nih.gov/pubmed/35668931
http://dx.doi.org/10.3389/fphar.2022.858207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9163401/
https://www.ncbi.nlm.nih.gov/pubmed/35668931
http://dx.doi.org/10.3389/fphar.2022.858207

Ejemplares similares